Experience of 8 Patients with Schizophrenia with Combined Use of Two Types of Long-Acting Injections Toshiaki Tsuneoka 1,2 , Satoru Sugisawa 3 , Sumiko Nakamura 4 , Sachiko Yokoyama 2,5 , Mari Yamada 1,2 , Ryotaro Sato 1,2 , Hironori Somemura 1,2 , Hayato Shimizu 1,2 , Dan Nakamura 1,2 , Kentaro Horiuchi 2,5 , Hiroki Yamada 2,5 , Akira Iwanami 1,2 1Showa University Karasuyama Hospital, Tokyo, Japan 2Department of Psychiatry, School of Medicine, Showa University 3Department of Hospital Pharmaceutics, School of Pharmacy, Showa University 4Komagino Hospital Pharmaceutics 5Showa University Northern Yokohama Hospital Keyword: 持効性注射剤 , long-acting injection , 併用療法 , combination therapy , 統合失調症 , schizophrenia pp.527-535
Published Date 2021/4/15
DOI https://doi.org/10.11477/mf.1405206322
  • Abstract
  • Look Inside
  • Reference

 A long-acting antipsychotic(LAI) is effective in treating schizophrenic patients by stabilizing the blood level. The single LAI dose may be insufficient and may be combined with oral medication, but there is also a risk of recurrence due to low adherence. At our hospital, combination therapy of two types of sustained-release injections were given to 8 patients. The CP conversion value of the oral drug was reduced from an average of 1100.9 to 543.8 by the combined use of LAI, and 4 patients did not take the oral antipsychotic drug. Of the 8 cases, 7 were discharged and 6 were living in the community without being readmitted.

 The problem of side effects is large, and the target is already high-dose multidrug therapy, and ECT and clozapine cannot be selected. It was suggested that the combination therapy may be effective in supporting discharge and maintaining community life.

Copyright © 2021, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-126X 印刷版ISSN 0488-1281 医学書院